Literature DB >> 30112267

Simultaneous Selective Dorsal Rhizotomy and Baclofen Pump Removal Improve Ambulation in Patients with Spastic Cerebral Palsy.

T S Park1, Brandon A Miller1, Junsang Cho1.   

Abstract

BACKGROUND: Intrathecal baclofen (ITB) administration via an implanted programmable pump and selective dorsal rhizotomy (SDR) are both used for the treatment of cerebral palsy (CP) spasticity.
OBJECTIVE: To examine whether SDR can improve ambulation in children who have been receiving ITB therapy for spastic cerebral palsy.
METHODS: We reviewed 13 patients who received prior ITB placement with subsequent simultaneous SDR and ITB removal. Patients also completed a follow-up survey to document long-term motor function.
RESULTS: In our 13-patient cohort, patients received ITB treatment for an average of 4.4 [Formula: see text] 1.8 years and the mean age of ITB removal/SDR was 12.5 [Formula: see text] 5.8 years. The follow-up period ranged from 3 to 19 months (mean duration: 6.9 [Formula: see text] 5 months). Pre-operatively, all patients had Gross Motor Function Classification System (GMFCS) scores between 2 and 4. Nine patients were diagnosed with spastic diplegia, two had spastic triplegia and two had spastic quadriplegia. SDR and ITB removal led to improved lower limb spasticity and ambulation. GMFCS scores remained stable in all patients. One patient developed a cerebrospinal fluid (CSF) collection in the abdominal wall due to a CSF leak from the baclofen pump site. All 11 patients who completed the follow-up survey noted improved motor function.
CONCLUSION: This study demonstrates that SDR can reduce spasticity and improve mobility after years of ITB treatment for spastic cerebral palsy.

Entities:  

Keywords:  cerebral palsy; intrathecal baclofen pump; neurosurgery; selective dorsal rhizotomy; spasticity

Year:  2018        PMID: 30112267      PMCID: PMC6089480          DOI: 10.7759/cureus.2791

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  8 in total

1.  Transient paralysis after intrathecal bolus of baclofen for the treatment of post-selective dorsal rhizotomy pain in children.

Authors:  I E Soliman; T S Park; M C Berkelhamer
Journal:  Anesth Analg       Date:  1999-11       Impact factor: 5.108

Review 2.  Gait function and decline in adults with cerebral palsy: a systematic review.

Authors:  P Morgan; J McGinley
Journal:  Disabil Rehabil       Date:  2013-04-17       Impact factor: 3.033

3.  Surgical techniques of selective dorsal rhizotomy for spastic cerebral palsy. Technical note.

Authors:  Tae Sung Park; James M Johnston
Journal:  Neurosurg Focus       Date:  2006-08-15       Impact factor: 4.047

4.  The gross motor function classification system for cerebral palsy: a study of reliability and stability over time.

Authors:  E Wood; P Rosenbaum
Journal:  Dev Med Child Neurol       Date:  2000-05       Impact factor: 5.449

5.  Toxicology of baclofen continuously infused into the spinal intrathecal space of the dog.

Authors:  M B Sabbe; M R Grafe; B L Pfeifer; T H Mirzai; T L Yaksh
Journal:  Neurotoxicology       Date:  1993       Impact factor: 4.294

6.  Surgical treatment of spasticity in children: comparison of selective dorsal rhizotomy and intrathecal baclofen pump implantation.

Authors:  Peter Kan; Judith Gooch; Aminullah Amini; Diana Ploeger; Barbara Grams; Wende Oberg; Sara Simonsen; Marion Walker; John Kestle
Journal:  Childs Nerv Syst       Date:  2007-09-05       Impact factor: 1.475

7.  Adults with cerebral palsy: a workshop to define the challenges of treating and preventing secondary musculoskeletal and neuromuscular complications in this rapidly growing population.

Authors:  Laura L Tosi; Nancy Maher; D Winslow Moore; Murray Goldstein; Mindy L Aisen
Journal:  Dev Med Child Neurol       Date:  2009-10       Impact factor: 5.449

8.  Selective dorsal rhizotomy as an alternative to intrathecal baclofen pump replacement in GMFCS grades 4 and 5 children.

Authors:  Harshal Ingale; Ismail Ughratdar; Samiul Muquit; Ahmad A Moussa; Michael H Vloeberghs
Journal:  Childs Nerv Syst       Date:  2015-11-09       Impact factor: 1.475

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.